AdAlta Engages Dark Horse for FDA Pre-IND Meeting on BZDS1901

Specialist FDA Support Secured for BZDS1901 Development

AdAlta Limited (ASX:1AD) has taken a strategic step by engaging Dark Horse Consulting Group, a seasoned cell and gene therapy consultancy, to guide its regulatory interactions with the US Food and Drug Administration (FDA) for its lead CAR-T therapy, BZDS1901. This collaboration aims to ensure that manufacturing, preclinical studies, and Phase 1 clinical trial designs are tightly aligned with FDA standards ahead of formal submissions, notably a pre-IND meeting that can smooth the path to clinical trial approval.

Such early regulatory engagement is widely regarded as critical in minimising delays and costly additional data requests. By tapping Dark Horse’s deep expertise, which includes supporting over 350 companies globally and numerous pre-IND meetings annually, AdAlta is positioning BZDS1901 to benefit from the FDA’s established frameworks and potential accelerated review pathways.

Clinical Promise in a Tough Cancer Market

BZDS1901 is a first-in-class CAR-T therapy targeting advanced mesothelioma, a rare and aggressive cancer with limited treatment options. The therapy has demonstrated multiple tumour responses, including two rare complete tumour clearances still ongoing at 6 and 22 months post-treatment. These outcomes stand out given the dismal prognosis and low response rates for second-line mesothelioma patients, where complete responses are almost unheard of.

AdAlta’s approach builds on promising clinical data reported in China, where BZDS1901 achieved up to a 50% overall response rate and 20% complete response rate in relapsed patients, alongside median survival extending beyond 25 months in earlier cohorts. This contrasts sharply with current standard therapies, which typically yield median survival under 18 months and rare complete tumour clearance.

These encouraging results enhance the therapy’s commercial appeal, addressing a US$4.2 billion segment of the advanced mesothelioma market. The company’s recent moves to transfer manufacturing to Australia and secure regulatory approvals are part of its broader East-to-West strategy to integrate Asian innovation with Western regulatory and commercial ecosystems, as detailed in its recent Australian manufacturing transfer and FDA and manufacturing milestones announcements.

Regulatory Pathways Could Accelerate Development

Beyond preparing for the IND submission, Dark Horse will advise on potential expedited regulatory designations that could accelerate BZDS1901’s development timeline and enhance its attractiveness to partners. These pathways, designed for therapies addressing rare diseases and unmet needs, can offer benefits such as priority review, accelerated approval, and commercial incentives.

AdAlta’s CEO Dr Tim Oldham highlighted the strategic importance of this engagement, noting that aligning with the FDA’s expectations not only facilitates efficient trial approvals but may also open doors to accelerated pathways that shorten time to market and improve commercial prospects.

Dark Horse’s role will include a regulatory gap analysis, review of the manufacturing technology transfer with Cell Therapies Pty Ltd, and preparation of briefing materials for the pre-IND meeting. This comprehensive support aims to streamline the regulatory process while positioning BZDS1901 for future global oncology partnerships.